Rigel Pharmaceuticals Inc (RIGL) Opciones

Titles of olutasidenib presentations at ASCO:
1. Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia.
2. Patients with relapsed/refractory mIDH1 AML who proceeded to transplant after olutasidenib treatment.
3. Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.

RIGL under $2

RIGL under $2

Just published, "Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)". The results of this phase 2 study support data from registrational cohort demonstrating that Olutasidenib works well in patients previously treated with venetoclax.
https://pubmed.ncbi.nlm.nih.gov/38538632/

Good read on Olutasidenib
https://journals.lww.com/oncology-times/fulltext/2024/03000/olutasidenib_as_a_breakthrough_for_r_r_midh1_aml.25.aspx
Important further research: 1) studying whether olutasidenib can eliminate the stem cell fraction within each patient's IDH1-mutant AML; 2) characterization of synthetic lethality involving olutasidenib in IDH1-mutant AML.

Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
FEBRUARY 22, 2024 7:50AM EST
GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer
Acquisition of established U.S. marketed product further expands Rigel's portfolio and leverages Rigel's existing infrastructure in both the institutional and community settings
GAVRETO generated ~$28M in U.S. net product sales in 2023

Rigl should be VTGN (Today) one day.

Yeah. Should be good Q.

Hopefully, the inducement grants are being used to hire qualified talent, rather than pad the wallets of friends and relatives.

Better be good.

Ugly.

nice

nice

base

What a shoot! Amazing.

The next quarter fin should include the rev for TAVALISSE. "In April, Rigel's partner Kissei announced the launch of TAVALISSE in Japan for the treatment of chronic ITP."
1. What else should we expect as for the rev?
2. Result of phase 3 of Fostamatinib3 COVID 19?
3. Status of Fostamatinib-ACTIV4 COVID 19?
4. Partnered Programs?

nice fins

gem

gem

easy

Nice spike AH today.

Higher low higher low.... next leg is North.

https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100

https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100

acting wild atm, but still healthy.

nice

Nice & Healthy.

quite the dip

ready

ready

red to green

red to green

Wonderful!

beauty

nice

Expect Q4 filing this week?

Be seeing that. Lot of 1.95 transactions so far

Revenue potential appears good. SP is slowly rising, and looks like it has been in accumulation for the past few weeks.

SP should be a lot higher since the Q4 revenue is more than double from last year...

Apparently insider buying reported on ST. Take it for what it’s worth.

RIGL news out

Looks like it will poke thru & bye bye 1 today.

Just like ABQQ. Right?

You are 1/2 way there!!!!

Wow - BOOM - we just went over a dollar - next step $10.00 - DON'T MISS OUT!!

This is a $10.00 per share stock in the very near future - EASILY!!

I just bought in. Seems like a good run could come in the near future.

Consolidating nicely on Continuation from last week!

LOL!

GIVE ME MY $2DOLLAS…YA BUM